In order to further elucidate the observed antitumor effects generated by bortezomib and SAHA in tumor-bearing mice (Figure 1), we examined the effect of bortezomib and SAHA treatment on the susceptibility of TC-1 cells to CD8+ T cell-mediated killing. Here, CD8A is linked to neoplasm.